E

A dozen early stage clinical trials to watch out for at AACR24

In 2011 we did an annual ASCO highlight video reel of what to watch out for. Three phase 1…

March 14, 2024
E

10 things I learned about ADCs at AACR 2024

The good, the bad, and the ugly under belly of the next flurry of ADCs

March 8, 2024
E

Exploring novel targets and modalities in advanced cancer

Where we look at half a dozen emerging agents and put them through their paces

February 6, 2024
E

Thinking outside the box

It's time to look to the future beyond plain vanilla ADCs

January 17, 2024
E

Key oncology take aways and insights from Days 1 and 2 at JPM24

Winners and losers at JPM24

January 10, 2024
E

An up and coming biotech not at JPM

Next generation CAR-T cells are coming to the clinic in 2024

January 8, 2024
E

A look at T cell therapies at ASH23

10 IO topics to watch out for at ASH23

December 5, 2023
E

Seeing the wood from the trees at ASH23

How a competitive landscape can change drastically over a short time

November 27, 2023
E

Unveiling the science behind a new IO strategy

A look at the potential missing piece in making bispecifics even better

November 10, 2023
E

Pointing the IO way

Eight key areas to watch out for at SITC 2023!

October 27, 2023
E

How bispecific antibodies are reshaping cancer treatment

After a long wait, finally some encouraging data in advanced solid tumours!

October 21, 2023
E

ESMO Preview 2 – Making sense of controversy

There's a huge surge in ADCs in the clinic but how many will make an impact?

October 2, 2023
E

ESMO23 Preview 1 – Hype over Hope?

Parsing cancer research hype at ESMO23

September 27, 2023
E

Early stage oncology data of interest in TARGETS23 preview

A look at some hot topics from the TARGETS/TRIPLE meeting in Boston

September 20, 2023
E

Gunning for new targets, new approaches

From CAR-T cells to protein degradation

September 19, 2023
E

What science tells us about future directions in lung cancer

What we can learn from scientific talks at WCLC in order to improve clinical development

September 13, 2023
E

Adding up the evidence

Early-stage agents in development for multiple myeloma - hit or miss?

September 7, 2023
E

Taking Myeloma by the Horns

Challenges and opportunities in the myeloma niche

August 31, 2023
E

The ADC merry-go-round

Part 2 of our WCLC 2023 Previews

August 22, 2023
E

Playing with fire

Some perspectives on the balancing act required between stimulus and response

August 9, 2023
E

Wow, just wow!

When an established concept is finally coming of age with new colours...

August 3, 2023
E

Important and novel research to be inspired by

Highlighting some outstanding research to take note of

July 25, 2023
E

A window into the future of IO

Where a forgotten costimulator may hold the key to new developments

June 28, 2023
E

A look at early stage trials debuting at ASCO23

What do three phase 1 and one phase 2 trials tell us about future development?

June 5, 2023
E

On TIGIT, ADCs, and other stories

Some ASCO23 abstracts to watch out for and why

May 31, 2023
E

The road less travelled

Off the beaten track can bring danger and delight in the unknown in equal measure

May 2, 2023
E

ASCO23 Preview 1 – W2W4 in Developmental Therapeutics

Update on Developmental Therapeutics

April 27, 2023
E

AACR23 Insights on gems from the poster halls – Part 1

Where we explain what to look for in 10 posters presented at AACR23

April 25, 2023
E

AACR23 – Is there an ADC renaissance on the horizon?

A look at some early stage ADC molecules in the clinic

April 19, 2023
E

AACR23 Preview 4 – Stepping It Up

Continuing our evaluation and exploration of another batch of early stage anti-cancer compounds either…

March 20, 2023
E

AACR23 Preview 3 – Emerging agents with a different mechanism of action

As we continue our new products journey evaluating early stage agents in development with data at…

March 16, 2023
E

A lysing kind of winter

Improving cell therapy performance with a multitude of innovative strategies

March 7, 2023
E

New directions in lymphomas

What will be the emerging products and regimens to watch out for in aggressive lymphomas?

January 31, 2023
E

Pointing the way forward

How can performance of T cell therapy be improved?

January 11, 2023
E

Kaizen in action

The evolving BMS-Celgene pipeline and what's coming next in new developmental twists

January 10, 2023
E

Shining the light

How novel bispecifics might help potentiate the impact of KRAS inhibitors when combined with checkpoint blockade

January 9, 2023
E

Moving targets

Ten emerging development areas to watch out for in oncology during 2023

January 5, 2023
E

Tilting at windmills

The importance of T cell exhaustion and exploring ways to avoid it

December 5, 2022
E

Emerging biotechs and novel IO concepts to watch out for

10 early stage IO biotechs to watch out for

November 30, 2022
E

Leaves of grass

Half a dozen key posters to watch out for in early stage oncology at SITC22

November 9, 2022
E

SITC Preview 2 – a look at novel and emerging IO targets

Five areas of early stage IO developments to watch out for

October 14, 2022
E

Dawn of new directions for protein and glue degraders

Where is the TPD field likely headed with next generation approaches?

October 4, 2022
E

Fishing for Gems from the Poster Halls Part 1

Bispecifics come and bispecifics go as companies seek to find a balance

September 29, 2022
E

Analysis of the CodeBreak 200 trial in lung cancer

An in-depth look at some of the issues impacting Amgen's pivotal trial and what it means for their competitors

September 14, 2022
E

ESMO22 Developmental Therapeutics Preview on Immunotherapies

In our latest ESMO conference preview it’s time to pick some early stage immunotherapy highlights…

August 31, 2022
E

New controversies in GI malignancies

What to watch out for in colorectal cancer, cholangiocarcinoma and hepatocellular carcinoma

August 24, 2022
E

New directions in small cell lung cancer

A look at promising new approaches in SCLC

August 12, 2022
E

A critical review of five different targeted therapy approaches at ASCO

Where five different targeted therapies are put through their paces

June 13, 2022
E

ASCO22 Highlights from Day 1

When cell therapies and targeted therapies collide

June 4, 2022
E

Five key areas to watch out for at ASCO22

Five key areas to watch out for at ASCO22

June 1, 2022
E

A journey that never ends

Can NK cells help checkpoint blockade work more effectively?

April 27, 2022
E

An inconvenient truth

Looking beyond the hype from a broader perspective

April 18, 2022
E

Off the beaten track in the bispecific landscape

Everything you needed to know about bispecifics at AACR22 and more!

March 31, 2022
E

5 important topics to watch out for at AACR22 on bispecifics

5 areas to watch out for on the bispecific antibody front

March 25, 2022
E

Challenges and opportunities with two different onco modalities

The latest on bispecifics and protein degraders

March 10, 2022
E

Aspiring to new heights – and new modalities

Can a different twist on modality make a real difference and go beyond what we already have?

March 4, 2022
E

What to watch out for on the CAR-T cell therapy front

Several controversies abound in the CAR-T cell niche this year, plus what's coming next?

December 7, 2021
E

Can bispecifics succeed where ADCs have failed?

Finessing oncology targets can be both tricky and challenging. Does changing the modality help?

November 23, 2021
E

Lessons learned from SITC – Part 1

Sometimes we learn more from failure than we do from success

November 16, 2021
E

An immunotherapy for the long run – or tail

With SITC fast coming up this week, immunotherapies in all sorts of shapes and guises are very much…

November 8, 2021
E

Scores on the doors in the TIGIT niche

Update on the various runners and riders in the TIGIT niche

November 3, 2021
E
Washington DC in Fall

SITC21 – What to Watch out for

SITC 2021 Preview

October 22, 2021
E

New developments on the lymphoma horizon

Key learnings and highlights from the recent AACR DLBCL specialist meeting

October 5, 2021
E

When things fall apart

One of the things that struck me at this year’s ESMO conference was the sheer variety and richness…

September 29, 2021
E

Storm Clouds or Sunny Skies? What’s on the horizon for Early Stage IO Development Data at ESMO21

A hard look at some IO agents in early development at ESMO21

September 18, 2021
E

WCLC21 Preview of key data to watch out for

What's hot at WCLC21?

August 19, 2021
E

A novel target to explore in prostate cancer

Is it a marker or a target? Actually, what is the target - and why does it matter?

August 5, 2021
E

Novel anti-cancer agents to watch out for

A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences

April 30, 2020
E

Gritting it out

What are Gritstone up to behind the scenes and where are they headed in the near-term?

July 20, 2021
E

New developments on the T cell engager front

Update on the T cell engager niche with an emerging agent of interest

July 8, 2021
E

Advent of a new era in advanced prostate cancer treatment

A look at the first anti-cancer therapy with a radiopharmaceutical in advanced prostate cancer

June 3, 2021
E

Dancing with proteins at the Masquerade

Who's going to the masquerade ball and how might they fare in the future?

June 1, 2021
E

The Future of Cell and Gene Therapies

13 ways in which CAR based or gene therapies can improve on current approaches to cell therapies

April 22, 2021
E

Highlights and commentary on key AACR21 data presentations

13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?

April 13, 2021
E

AACR21 Preview 8 – The growing bispecific niche

A rock around the bispecific clock highlighting key presentations coming at the AACR 2021 virtual meeting

April 8, 2021
E

Novel combination strategies to enhance KRAS inhibitors

Combinations will be the future for KRAS inhibitors but which ones and why? Includes some new ideas!

March 16, 2021
E

Emerging developments and trends in advanced lung cancer

Gems from the WCLC20 poster hall which may make an impact

February 9, 2021
E

A look at the exon 20 landscape in lung cancer

A look at the exon 20 insertion landscape - all to play for!

February 4, 2021
E

Parallel lines: opportunities and challenges in GI cancers

Important developments on the GI cancer front to watch out for

January 19, 2021
E

Strategic direction and future impacts in multiple myeloma

A rock around the myeloma clock through the eyes of a KOL - what stood out and what did not?

January 14, 2021
E

How bispecifics will make an impact in myeloma

Beyond CAR-T cell therapy there are novel bispecifics coming along so where and how will they fit in?

January 13, 2021
E

An exciting pipeline of early stage oncology agents from BMS

A critical look at the early stage BMS oncology pipeline

January 11, 2021
E

Future of NK Cell Therapy – Part 2

Commentary on engineered NK cells, including CAR-NK and memory-like NK cells

January 6, 2021
E

Future of NK Cell Therapy – Part 1

Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?

January 5, 2021
E

A critical review of bispecific antibodies at ASH20

What caught our attention on novel bispecific antibodies at ASH20?

December 7, 2020
E

ASH20 Preview of progress with bispecific antibodies

Updated look at the bispecific landscape in early clinical development

November 9, 2020
E

Potential new targets and biomarkers for immunotherapy

How we can learn more from failure in clinical trials so we can improve outcomes further with emerging agents in early development

October 20, 2020
E

A contrarian view of key cancer trial results

Winners, losers and risers... who goes where in the final analysis?

October 8, 2020
E

ESMO20 Preview 4 – Targeted therapies to watch out for

What to watch out for this weekend in targeted therapies and early stage new product development

September 17, 2020
E

ESMO20 Preview 3 Developmental Therapeutics – IO therapies

Five IO areas in early stage development to watch out for at ESMO20

September 15, 2020
E

ESMO20 Preview 2 – New Targets, New Opportunities

Can we predict the future cancer drug combinations from emerging new targets?

September 10, 2020
E

Making a splash in the competitive CAR-T space

If we were to tackle CAR T cell therapy design differently, how would we go about doing it?

July 13, 2020
E

New developments in CAR-T cell therapies including controversial ones

The ups and downs of CAR-T cell therapy development continues apace

July 8, 2020
E

Are gamma delta T cells ready yet for prime time?

Update on the Gamma Delta T cell niche - what's new, what's up, and what's down?

July 1, 2020
E

Looking through the window at some novel new product development concepts in oncology

A look at some novel and promising approaches in early oncology new product development

June 24, 2020
E

Who is winning the CD20xCD3 Bispecific Race to Market?

An update on the CD20 x CD3 bispecific with expert commentary on data at ASCO EHA.

June 15, 2020
E

AACR20 – Ten New Directions in Early Cancer Drug Development

Ten intriguing novel agents in early development to watch out for

April 23, 2020
E

Unlocking novel IO targets and anti-cancer agents in early development

When T cells stop working how can we get innate immune cells like NK cells to take up the slack and help track down tumours?

March 24, 2020
E

The dog that didn’t bark

A look at what happened from the DREAMM1 to DREAMM2 trials exploring the BCMA ADC belantamab mafadotin in refractory multiple myeloma and why GSK have a challenge ahead

December 17, 2019
E

In Plain Sight

A look at some of the highly ranked clinical data presented over the weekend in Orlando

December 9, 2019
E

ASH19 10 innovative approaches in Hematologic Malignancies

Some hidden gems and under the radar abstracts that may appeal to the off-Broadway crowd at ASH19

November 19, 2019
E
National Harbor Maryland

Key Highlights from Day 1 at SITC19

If we want to improve on the current results with IO therapies then we need to go to basics and understand the biology of each disease subset in the context of what we've learned so far

November 8, 2019
E

Targeting NRG1 Gene Fusions

What did we learn at #Targets19 about targeting NRG1 gene fusions with MCLA-128?

October 27, 2019
E

Insights on the Jounce-Celgene collaboration and ICOS agonism

Thoughts and commentary on the Jounce-Celgene collaboration update and the emerging ICOS landscape

July 24, 2019
E
AMG 596 EGFRvIII BiTE

A look at Amgen’s early oncology pipeline

Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?

July 18, 2019
E

Will innate bispecifics make a difference in hematologic malignancies and solid tumours?

What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess

July 11, 2019
E

The Next Wave of IO with Dr Dan Chen

We saw a number of challenges emerge with immune agonists as antibodies and now companies are experimenting with them in bispecifics - what needs to be considered to make them work? What will the next wave of IO look like?

July 9, 2019
E

How failure allows us to continually innovate

How the design of different cancer approaches can affect clinical performance

June 24, 2019
E

Key highlights on lymphomas from iCML

Round-up and analysis of key lymphoma data at iCML 2019

June 20, 2019
E

Insights from CIMT in Mainz Part 2

Highlights (and lowlights) from Day 2 of immunotherapy presentations at CIMT 2019 in Mainz.

May 23, 2019
E

What to watch out for in Bispecifics at ASCO19

A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.

May 28, 2019
E

Going beyond BCMA as a target in multiple myeloma

Is there a better way to target myeloma than with BCMA alone? Data suggests there's plenty of room for improvement.

April 22, 2019
E

Defense is the Best Attack – Part 1

Update on T cell bispecifics and other key topics in early stage IO development

March 12, 2019
E

How do we improve on 1st Generation T cell bispecifics?

An upcoming small biotech focused on IO targets with their novel platform approach

January 28, 2019
E

The Yin and Yang of biomarkers in cancer research

Some examples of potentially useful biomarker inclusion in early oncology trials

January 22, 2019
E

Insights from the ASCO GI19 conference

What to watch out for at the ASCO GI19 conference in San Francisco

January 17, 2019
E

A tale of two cities – a look at two small immunotherapy biotechs

Going beyond anti-PD1 checkpoint blockade is important if we want to help more people respond to cancer immunotherapy

January 14, 2019
E

The challenges of bispecifics

FDA slaps a partial clinical hold for unwanted side effects, now what?

December 11, 2018
E

ASH18 Highlights from Day 3

Review of a round dozen key abstracts at #ASH18, both scientific and clinical data is under the microscope!

December 3, 2018
E

ASH18 Highlights from Day 2

We offer 13 key highlights from day 2 of ASH18, including some surprises.

December 2, 2018
E

ASH18 Preview 3 – BCMA

From one BCMA directed CAR in 2015, we now have a very competitive niche in multiple myeloma. What's in store?

November 26, 2018
E

SITC18 Preview and IO curiosities

An extensive round-up of what to expect from SITC18 ahead of the abstract reveal

November 2, 2018
E

Learnings from IO combinations and where we’re headed

Lessons learned from recent failure and a look at where a few new developments might be coming from...

August 23, 2018
E

Preview of CICON18 – Part 1

Part 1 of our #CICON18 Previews - a look at 11 intriguing IO related studies

September 20, 2018
E

New Insights on BCMA BiTEs and CAR T cell therapies in Myeloma

Update on BCMA, SLAMF7 and other targets in multiple myeloma

September 11, 2018
E

Pathways to success with NK cell therapy

Will NK cell engagers have a positive impact on checkpoint therapy and other adaptive immunotherapies?

August 28, 2018
E

In a Prudential Light

Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.

June 19, 2018
E

A different take on targeting cancer

How do we drive more T cells into the tumour? Here's one company who are looking to do just that.

May 8, 2018
E

A look at an up and coming west coast biotech

A look at the pipeline of the up and coming Seattle biotech, Alpine Immune Sciences

January 22, 2018
E

The Future of Multiple Myeloma

A look at key pipeline developments in multiple myeloma through the lens of a global expert in the field

January 2, 2018
E

Update on CD123 and other viable targets in AML

With increasing evidence that CD123 is a suboptimal target in AML, what other approaches might be more useful to consider?

October 17, 2017
E

AACR18 Day 2 Highlights

A look at the Class of 2018 new products in development - a hit or miss?

April 16, 2018
E

Jumpstarting the immune system with synthetic immunity

Jumpstarting the immune system with a synthetic immunity approach - how can we do this?

August 2, 2017
E

A hidden gem at ASCO17

How can we boost the efficacy of checkpoint therapies? One way is to drive more activated T cells into the tumour.

August 1, 2017
E

A promising IO combo approach to watch out for

Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...

June 19, 2017
E
ASCO 2014 Chicago Contemplation

An up and coming area in early oncology R&D

A look at an up and coming niche in cancer research that may turn out to be useful in conjunction with checkpoint blockade

May 22, 2017
E

One Step Beyond

With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.

July 5, 2016
E

Xencor and Novartis storm the hematologic bispecific market

The oncology bispecific market is heating up with J&J collaborating with Macrogenics and Novartis with Xencor. We discuss the skinny...

June 28, 2016
E

Beyond Blinatumomab – Update on Bispecific T cell Engagers

In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.

March 31, 2016
E

How do we boost the effectiveness of checkpoint inhibitors?

A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.

November 2, 2015
E

Top 10 #ASH17 abstracts to watch out for

The Mav's key oral abstracts to follow at #ASH17 -- warning this list includes quirky selections!

November 30, 2017
E

Next generation approaches to immuno-oncology – where next?

What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?

January 8, 2015